I In nt tr ro od du uc ct ti io on n. . Brain arginine 8 -vasopressin (AVP), through the V 1a -and V 2 -receptors, is essential for the maintenance of mean arterial pressure (MAP). Central AVP interacts with the components of the renin-angiotensin system, which participate in MAP regulation. This study aimed to determine the effects of V 1a -, V 2 -and V 1a /V 2 -AVP selective antagonists and AT 1 -and AT 2 -angiotensin II (Ang II) selective antagonists on the MAP induced by AVP injected into the medial septal area (MSA) of the brain. M Ma at te er ri ia al ls s a an nd d m me et th ho od ds s. . Male Holtzman rats with stainless steel cannulae implanted into the MSA were used in experiments. Direct MAP was recorded in conscious rats. R Re es su ul lt ts s. . AVP administration into the MSA caused a prompt and potent pressor response in a dose-dependent fashion. Pretreatment with the V 1a -and V 2 -antagonists reduced, whereas prior injection of the V 1a /V 2 -antagonist induced a decrease in the MAP that remained below the baseline. Both AT 1 -and AT 2 -antagonists elicited a decrease, while simultaneous injections of two antagonists were more effective in decreasing the MAP induced by AVP. C Co on nc cl lu us si io on n. . These results indicate there is a synergism between the V 1a -and V 2 -AVP and AT 1 -and AT 2 -Ang II receptors in the MSA in the regulation of MAP.
Introduction
Several lines of evidence suggest that central arginine 8 -vasopressin (AVP) plays a role in the control of mean arterial pressure (MAP) in both normotensive and hypertensive animals. Administration of AVP into the central nervous system (CNS) produces changes in MAP that can be reversed by competitive antagonists. The cardiovascular responses to AVP are due to a central effect and not to leakage of the peptide into the periphery as they are blocked by central but not peripheral administration of specific AVP-receptor antagonists. [1] [2] [3] Binding sites for AVP have been located in several regions of the rat brain including the medial septal area (MSA). [4] [5] [6] The pharmacological pressor effect of V 1 -agonists and AVP has been shown to stimulate phosphoinositide hydrolysis in the MSA. 7, 8 Central administration of AVP 7 decreased the [ 3 H]-AVP equilibrium K d and number of AVP-receptors in the MSA of homozygous but not heterozygous rats, and this decrease in receptor number was accompanied by a decrease in the post-receptor response to AVP as measured by AVP stimulation of [ 3 H]-inositol 1-phosphate accumulation. It appears from these studies that the influence of AVP on its receptor is highly complex. [7] [8] [9] The nature of receptors mediating central cardiovascular effects of AVP is not clear. In the rat and rabbit, central pressor effect appears to be mediated by V 1 -receptors. 10, 11 On the other hand, it has been suggested that V 1 -and V 2 -like receptors mediate the enhancement of baroreflex by circulating AVP. 12, 13 It has been proposed that the cardiovascular effects of AVP are mediated through at least two receptor subtypes: the V 1a -receptor, which is found on vascular smooth muscle cells and in the myocardium, and V 2 -receptor, which is found in the distal tubule of the kidney.
14 Stimulation of the V 1a -receptors results in vasoconstriction in the peripheral and coronary circulation 15 and chronic V 2 -receptor stimulation increases basal MAP. 16 Several studies 17, 18 have demonstrated the existence of all components of the renin-angiotensin system (RAS), including angiotensin II (Ang II)-receptors, in the CNS. The AT 1 -receptor, a major subtype of Ang II-receptors, is dominantly localised in the regions that control AVP secretion. [19] [20] [21] In addition, both AT 1 -and AT 2 -receptors are expressed in the forebrain and brain stem, which are related to the regulation of MAP. 17 Moreover, the AT 2 -receptors are also located in the hypothalamus 22 and are predominantly expressed in the ventral part of the brain. 23 AT 1 -and AT 2 -binding sites are also evidenced in the MSA. 24, 25 Considering the importance of the MSA in the MAP regulation in rats, the present experiments were designed to determine the participation of V 1a -and V 2 -vasopressinergic receptors, as well as the effects of the AT 1 -and AT 2 -Ang II receptors in the MAP induced by administration of AVP in the MSA.
Material and methods

Animals
Male Holtzman rats weighing 300-350 g were used.
The animals were housed in individual stainless steel cages with free access to normal sodium diet (Purina Rat chow 5012) and water. Temperature was maintained at a constant 23±2 o C, with a 12:12-hour light-dark cycle. The experiments were performed between 9 a.m. and 7 p.m.
Brain surgery
Rats were anaesthetised with an Equithesin anaesthetic cocktail (0.97 g sodium pentobarbital and 4.25 g chloral hydrate in 100 ml distilled water; 0.33 ml/100 g body weight) and placed in a Kopf stereotaxic instrument. Stainless steel cannulae (0.60 mm o.d., 0.33 mm i.d.) were implanted just above the MSA, using the bregma as a reference position. Cannula introduction points were made on the rats' heads and at these points, cranial bone trepanning was performed with a spherical drill opening holes with an approximate diameter of 1.5 mm. Stainless steel cannulae were implan ted at the following coordinates: 1.0-0.7 mm caudal to the bregma, 0.0 mm lateral to the sagittal line, and 10.2 mm below the duramater, in conformity to the rat brain atlas of Paxinos and Watson. 26 The tip of the cannula was positioned at a point 0.5 mm above the MSA. Cannulae were fixed to the skull using acrylic cement and small screws. Insertion of a close-fitting stylet kept the lumen free of debris and clots. Three days before and three days after surgery, the animal received prophylactic doses of penicillin. After brain surgery, the animals returned to their individual metabolic cages, with access to granular chow and tap water for one week, until the day of experiment. At the end of the experiments, the animals received an injection of 2 µl fast green dye into the MSA. The rats were anaesthetised with 2,2,2-tribromoethanol and perfused through the heart with 10% formalin. The brains were removed, frozen and then cut into 20-30 µm sections, stained with haematoxylin, and analysed by light microscopy to confirm MSA injection sites. The procedures complied with the U.S. National Institutes of Health Guide for Care and Use of Laboratory Animals.
Drugs
The following drugs were dissolved in phosphate buffer: (Arg Injections into rat brains were made using a Hamilton-type syringe (5 µl) connected to a PE-10 polyethylene tube and a needle (0.3 mm o.d.) that was 0.5 mm longer than the cannula fixed to the skull. A volume of 0.2 µl was delivered over 20-30 seconds.
MAP measurement
Four days after brain surgery, the animals were anaesthetised with tribromoethanol (20 mg/100 g body weight), a catheter was fitted into the femoral artery and another one into the jugular vein. Both catheters were terminated subcutaneously and exteriorised at the nape of the neck. The following day, the femoral catheter was connected to a Narco (P-1000B) pressure transducer coupled to a multi-channel recorder (Narcotrace 40Narco Bio-System, Austin, TX, USA). Direct MAP was recorded from the abdominal aorta in conscious, unrestrained, normovolemic rats. The baseline was defined when MAP remained stable for at least 5 min of continuous recording before any treatment. Each animal was subjected to only one day of cardiovascular recording.
Various concentrations (0.5, 1.0, 2.0, 4.0, 8.0 and 16.0 nM) of AVP and the antagonists were randomly assigned to each experimental day. Half of the animals received one dose of the antagonists in the first injection and half received the other dose. Then, the doses given were reversed in the second injection, which was given at least 6 h later. The antagonists were injected into the MSA immediately after the baseline recording, 20 min before 8.0 nM AVP was injected.
Histology
The animals used in the present experiment had the boundary between the medial septal and diagonal band nuclei set at the level of the large dorsally located Island of Calleja where a small, cell-sparse zone partially transected the complex, and medial septal nucleus became expanded laterally. The ventral part of the nucleus of the diagonal band reached the ventral surface of the brain.
A typical MSA injection site, as shown in figure 1 , was centered in the intermediate and caudal areas of the medial septum. In some rats, there was a small amount of fast green dye in the lateral ventricles and lateral septal area, and these were excluded from the analysis.
Statistical analysis
Peak variations in MAP, which occurred 5 min after MSA injection of AVP or/and injection of antagonists, were analysed by repeated measures analyses to variance that was performed to determine, overall, main effects or interaction. Significant effects were further evaluated by Newman-Keuls post hoc test with the level of significance set at p<0.05. Each animal submitted to arterial pressure recording received only two MSA injections separated by a six-hour interval. 
Results
Effects of V
Discussion
The role of AVP in the regulation of MAP in pathophysiological conditions such as hypovolaemia or hypotension has been characterised, 27 whereas its performance in the MAP in normal physiological situations is ill-defined. AVP is known to have an important role in the stimulation of vascular smooth muscle contraction through V 1a -receptors and that stimulation of the low-threshold V 1 -neurons may prevent excessive rises in MAP elevations during activation of the vasopressinergic system in the CNS by osmotic challenges. 28 Highly selective peptide and nonpeptide V 1a -receptor antagonists have been developed. 29, 30 Recent studies 31 have confirmed and extended previous pharmacological studies showing that V 1a -receptors mediate AVP-stimulated pressor responses. Furthermore, previous pharmacological studies with selective V 1a -receptor antagonists showed that blocking the V 1a -receptor did not lead to any significant change in basal MAP levels. [32] [33] [34] AVP exerts a variety of biological effects such as vascular resistance control through V 1a -receptors and regulation of water excretion through V 2 -receptors. It is generally assumed that AVP is involved in several conditions such as heart failure, hyponatremia and hypertension via the V 1a -and V 2 -receptors. 35, 36 The development of nonpeptide AVP-antagonists seems essential to the elucidation of the physiological and pathophysiological roles of AVP. Combined V 1a /V 2 -receptor antagonism resulted in reductions in systemic vascular resistance with increased cardiac output, as well as a substantial increase in urine output. Investigations with YM087 in receptor assay systems and animal models suggested substantial antagonism of both V 1a -and V 2 -receptors. 37, 38 Udelson et al. 39 demonstrated favourable short-term haemodynamic and renal effects of combined V 1a -and V 2 -AVP-receptor antagonism, as well as the lack of relation of these effects to baseline markers of AVP activation.
The present results demonstrated that increasing doses of AVP injected into the MSA increased the MAP in a dose-dependent manner. In agreement with the previous results, the prior injection of V 1a -antagonist into the MSA blocked the increase in the MAP induced by AVP. Furthermore, corroborating previous pharmacological studies with selective V 1a -receptor antagonists, the blockage of the V 1a -receptor did not lead to any significant deviation from the MAP baseline. Various doses of V 2 -AVP antagonist injected into the MSA partially impaired the AVPinduced MAP. Injections of the V 1a /V 2 -antagonist induced a decrease in the MAP to a level below the baseline. Therefore, this effect on the MAP was due to the combined V 1a /V 2 -receptor antagonism, which resulted in reductions in systemic vascular resistance and increases in cardiac output, as well as a substantial increase in urine output.
It has been reported 40 that body RAS is present in the CNS. Previous studies 17, 22, 23 showed the existence of both AT 1 -and AT 2 -receptors in the CNS. In the brain, the Ang II-receptors are involved in the pressor responses and AVP release. [41] [42] [43] It has also been demonstrated that intracerebroventricular injection of Ang II showed dose dependency on pressoric response. AT 1 -and AT 2 -receptors also induced a dose-dependent effect to block the increase in the MAP induced by AVP. 44 These results suggested that central AT 2 -receptors play an important role in the regulation of MAP combined with AT 1 -receptors.
Another aim of this study was to determine the contribution of the MSA AT 1 -and AT 2 -receptors on the MAP induced by AVP. The present results showed that the AT 1 -receptor antagonist abolished the MAP induced by AVP, whereas the AT 2 -receptor antagonist only impaired this effect. Concomitant administration of both Ang II-antagonists induced a greater decrease in MAP than either antagonist injected alone. Previous functional studies showed that AT 2 -receptors participate in the regulation of AVP released by Ang II into the hypothalamus. 44 It was suggested that a small number of losartansensitive sites in the brain are revealed when AT 2 -receptors are bound to AT 1 -receptors, or that PD-123319 and CGP42112A (antagonists of AT 2 -receptors) might increase the affinity of losartan to AT 1 -receptors.
In summary, blockage of MSA AVP-receptors with a V 1a -antagonist abolished the MAP induced by AVP, whereas pretreatment with the V 2 -antagonist only impaired this effect. When the V 1a /V 2 -AVP antagonist was injected prior to the AVP, the MAP was maintained below the control group (baseline). The present data also showed that MSA blockage of AT 1 -receptors showed a greater effect in decreasing the MAP compared with AT 2 -antagonist. The increase in MAP by AVP was abolished when losartan was injected together with CGP42112A. 
